Edwards Lifesciences backs FY14 EPS view 'around' $3.10, consensus $3.17 Sees FY14 total net sales growth 1%-10%. Sees FY14 gross profit margin approximately 73%. Sees FY14 free cash flow $325M-$425M. Guidance provided in slides presentation for William Blair & Company LLC Growth Stock Conference.
Senate Health, Education, Labor & Pensions Committee to hold a hearing The Committee holds a hearing entitled, "Continuing America’s Leadership: Advancing Research and Development for Patients" with Chairman & CEO Mussallem of Edwards Lifesciences on March 24 at 10 am. Webcast Link